ClinicalTrials.gg
Active, not recruitingNCT05793307Updated Nov 13, 2026

Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug

A Phase 1/2 interventional study of GC301 in Pompe Disease Infantile-Onset, sponsored by GeneCradle Inc. Active, not recruiting at 5 sites in China. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by GeneCradle Inc · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
Up to 6 Months
Sex
All
01

Study summary

This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with infantile-onset Pompe disease who are younger than 6 months old will be studied.

02

Conditions studied

  • Pompe Disease Infantile-Onset
03

In context

Glycogen Storage Disease Type II

162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.

This study's planned enrollment of 16 is below the median of 20 across 89 interventional studies indexed under Glycogen Storage Disease Type II.

Browse Glycogen Storage Disease Type II studies →

Lead sponsor

GeneCradle Inc is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age \< 6 months
  • Patient has diagnosis of infantile onset Pompe disease
  • The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated prior to any study-related procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Left ventricle (LVEF) \< 40%;
  • Patient who has AAV9 neutralizing antibody titer ≥ 1:100;
  • Patient who has received enzyme replacement therapy (ERT) more than twice;
  • Patient who has respiratory dysfunction before enrollment, including the blood oxygen (O2) saturation level \< 90%, or the partial pressure of carbon dioxide (PCO2) in venous blood > 55 mmHg, or PCO2 in arterial blood > 40 mmHg;
  • Patient who has laboratory abnormalities of: creatinine > (ULN), \< 90 g/L;
  • Patient with congenital organ absence;
  • Patient with a history of allergy;
  • Patient who is positive for human immunodeficiency () antibody, surface antigen, antibody, or treponema pallidum antibody;
  • Patient who has participated in a previous gene therapy research trial;
  • Patient who has any concurrent major disease or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Single intravenous administration of GC301 at a dose of 8.0 x 10\^13 vector genomes per kilogram body weight

    Genetic: GC301

  • Experimental
    Cohort 2

    Single intravenous administration of GC301 at a dose of 1.2 x 10\^14 vector genomes per kilogram body weight

    Genetic: GC301

  • Experimental
    Cohort 3

    Single intravenous administration of GC301 at a dose of 1.8 x 10\^14 vector genomes per kilogram body weight

    Genetic: GC301

Interventions

  • GeneticGC301

    GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene

06

What researchers measure

Primary outcomes

  1. Safety and tolerability over time

    Frequency of adverse events (AEs), serious adverse events (SAEs), and changes from baseline in relevant clinical laboratory tests

    Time frame: 52 weeks

  2. Proportion of patients treated with GC301 who are alive

    Time frame: 52 weeks

Secondary outcomes

  1. Proportion of patients treated w/ GC301 who were alive and free of ventilator support

    Time frame: 52 weeks

  2. Changes from baseline Left Ventricular Mass (LVM) annd LVMI (LVM index)

    Time frame: 26 and 52 weeks

  3. Changes from baseline creatine kinase (CK), CK-MB, Troponin I, B-Type Natriuretic Peptide (BNP)

    Time frame: 26 and 52 weeks

Other outcomes

  1. Change from baseline glycogen content in muscle tissue

    Time frame: 26 and 52 weeks

  2. Change from baseline acid alpha-glucosidase (GAA) enzyme in muscle and blood

    Time frame: 26 and 52 weeks

  3. Change in patient's motor function

    To evaluate the changes in patient's mobility and physical ability using Hammersmith Infant Neurological Examination (HINE) scores

    Time frame: 52 weeks

  4. The viral load of adeno-associated virus (AAV) vector

    To assess the change of AAV vector copy numbers within 52 weeks after administration.

    Time frame: At multiple time points from pre-dose through up to 1 years post-dose

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Dec 2025, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Mar 31, 2023
StartActual
Jun 2, 2023
Primary completionActual
Dec 31, 2025
CompletionEst.
Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and oversight details
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05793307
Lead sponsor
GeneCradle Inc
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Jun 2, 2023
Primary completion
Dec 31, 2025
Completion
Dec 2026 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion